INDIGO
Effective and Affordable Flu Vaccines for the World
Single-Shot. Effective. Affordable.
INDIGO is a research and innovation Project jointly funded by the European Commission, as part of the Horizon 2020 research and innovation program, and India’s Department of Biotechnology. The interdisciplinary Consortium consists of 17 partners from India, the European Union, and the United States.
The INDIGO program has been designed to develop next-generation influenza vaccines with low antigen dose and low cost. INDIGO aims at single-shot and cost-effective influenza vaccines to elicit optimal, robust, and durable antibody responses. This is highly desirable as it could increase the accessibility to influenza vaccines in India and other regions of the world regarded as low- to middle-income countries.
Where we work
“Vaccines are the single most important medical intervention for reducing morbidity and mortality during an influenza pandemic.”
— Dr. Margaret Chan, Former Director-General, World Health Organization
